Earnings Releases

INOVIO PHARMACEUTICALS, INC. reported financial results for the three months ended March 31, 2026.

“On May 13, 2026, Inovio Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.”

OMEROS CORP reported the three months ended March 31, 2026 results: net income Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, EPS $0.78 per share.

“On May 13, 2026, Omeros Corporation issued a press release announcing financial results for the three months ended March 31, 2026.”

CISCO SYSTEMS, INC. reported its fiscal third quarter 2026 ended April 25, 2026 results: revenue $15.8 billion, net income $3.4 billion or $0.85 per share, EPS $0.85. Guidance raised.

“sambadri@cisco.com CISCO REPORTS THIRD QUARTER EARNINGS News Summary: • Double-digit top and bottom-line growth exceeding the high end of our guidance ◦ Record revenue of $15.8 billion, up 12% year over year; GAAP EPS of $0.85, up 37% year over year; and non-GAAP EPS of $1.06, up 10% year over year ◦ GAAP gross margin of 63.6% and non-GAAP gross margin of”

Journey Medical Corp reported the three months ended March 31, 2026 results: revenue $16.0 million, net income $(2.2) million, or $(0.08) per share basic and diluted, EPS $(0.08) per share basic and diluted.

“Reports First Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold”

Tamboran Resources Corp reported preliminary financial results for the quarter ended March 31, 2026.

“On May 13, 2026, Tamboran Resources Corporation issued an earnings presentation and press release announcing its financial and operating results for the quarter ended March 31, 2026.”

Cytosorbents Corp reported first quarter ended March 31, 2026 results: revenue $8.9 million, net income $5.1 million or $0.08 per share, EPS $0.08 per share.

“CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update PRINCETON, N .J ., May 13, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2026, recent business highlight s, and provides a regulatory update. First Quarter 2026 Financial Results • Revenue was $8.9 million, an increase of 2% over the prior year, from $8.7 million • Gross margin was 69% in the quarter compared to 71% in Q1 2025 • Operating loss was $3.0 million, compared to $3.9 million in Q1 2025 • Net loss was $5.1 million or $0.08 per share, compared to a net loss of $1.5 million or $0.02 per share in Q1 2025.”

ClearPoint Neuro, Inc. reported first fiscal quarter ended March 31, 2026 results: revenue $12.1 million. Guidance reaffirmed.

“to the brain and spine, today announced financial results for its first quarter ended March 31, 2026. First Quarter 2026 Highlights • Reported first quarter revenue of $12.1 million, including $2.3 million of IRRA flow revenue, representing 43% overall growth and 16% year-over-year total organic growth compared with the first quarter of 2025; • The activated”

Dermata Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.

“On May 13, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the quarter ended March 31, 2026, and provided a corporate update.”

Snail, Inc. reported the first quarter ended March 31, 2026 results: revenue $27.3 million, net income $2.1 million.

“renown IPs and titles. We remain focused on unlocking the value of our pipeline and delivering results.” First Quarter 2026 Financial Highlights Net revenues increased 35.7% to $27.3 million compared to $20.1 million in the same period last year. The increase was primarily due to an increase of $4.2 million and $2.1 million in revenue related to ASA and Bellwright ,”

Equillium, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $5.3 million, or $(0.06) per basic and diluted share, EPS $(0.06) per basic and diluted share.

“On May 13, 2026, Equillium, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026”

Aptevo Therapeutics Inc. reported preliminary financial results for the period ended March 31, 2026.

“On May 13, 2026, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended March 31, 2026.”

Aquestive Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.

“On May 13, 2026, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the first quarter ended March 31, 2026 and provided an update on recent developments in its business.”

Doximity, Inc. updated its fiscal quarter and year ended March 31, 2026 guidance (initiated).

“On May 13, 2026 , Doximity, Inc. (“Doximity”) issued a press release announcing its financial results for its fiscal quarter and year ended March 31, 2026.”

Adicet Bio, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $20.2 million, or a net loss of $1.88 per basic and diluted share, EPS a net loss of $1.88 per basic and diluted share.

“On May 13, 2026, Adicet Bio, Inc. announced its financial results for the quarter ended March 31, 2026.”

Allogene Therapeutics, Inc. reported financial results for for the quarter ended March 31, 2026.

“Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2026 in the press release attached hereto as Exhibit 99.1”

Grocery Outlet Holding Corp. reported first quarter of fiscal 2026 ended April 4, 2026 results: revenue $1.17 billion, net income Net loss was $180.3 million, or $(1.83) per diluted share, EPS $(1.83) per diluted share.

“for the first quarter of fiscal 2026 ended April 4, 2026. Highlights for First Quarter Fiscal 2026 as compared to First Quarter Fiscal 2025: • Net sales increased by 3.6% to $1.17 billion. • Comparable store sales declined by 1.0%. • Gross margin was 29.6% compared to 30.4% last year, a decline of 80 basis points, including a 50 basis point impact from inventory”

Bionano Genomics, Inc. reported first quarter ended March 31, 2026 results: revenue $6.7 million.

“towards growing our business.” Q1 2026 Financial Results For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $6.7 million, representing an increase of 4% from $6.5 million compared to the first quarter of 2025. • Consumables revenue was $3.9 million, representing an increase of 20% compared to the”

Usio, Inc. reported first quarter ended March 31, 2026 results: net income net income of approximately $0.1 million, or $0.00 per share, EPS $0.00 per share.

“On May 13, 2026, Usio, Inc. issued a press release announcing financial results for its quarter ended March 31, 2026.”

STAAR SURGICAL CO reported First Quarter 2026 results: revenue $93.5 million, net income $5.2 million, EPS $0.10.

“STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter Net Sales of $93.5 million, highest first quarter Net Sales in Company’s history, up 119.6% Y/Y Net Income of $5.2 million, with GAAP EPS of $0.10”

Spero Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue Total revenue for the first quarter of 2026 was $0.3 million, net income Spero reported a net loss of $7.2 million for the first quarter of 2026, EPS diluted net loss per share of common stock of $0.13.

“Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.”

Lulu's Fashion Lounge Holdings, Inc. reported first quarter ended March 29, 2026 results: revenue $57.5 million, net income $4.1 million. Guidance reaffirmed.

“in extending our momentum and driving improved profitability, cash generation, and customer engagement throughout the year.” ​ First Quarter 2026 Highlights: ● Net revenue of $57.5 million, a 10% decrease compared to the same period last year, driven by a 15% decrease in Total Orders Placed and the impact of higher return rates driven primarily from sales mix,”

NATURAL GAS SERVICES GROUP INC updated its first quarter ended March 31, 2026 guidance (raised).

“On May 12, 2026, Natural Gas Services Group, Inc. (the “Company”) hosted an earnings call to announce the Company’s financial results for the first quarter ended March 31, 2026, and provide certain other financial and business information, along with forward guidance.”

Kentucky First Federal Bancorp reported three months ended March 31, 2026 results: net income $581,000, EPS $0.07 diluted earnings per share.

“announced net income of $581,000 or $0.07 diluted earnings per share for the three months ended March 31, 2026”

Kentucky First Federal Bancorp reported nine months ended March 31, 2026 results: net income $1.2 million, EPS $0.15 diluted earnings per share.

“Net earnings were $1.2 million or $0.15 diluted earnings per share for the nine months ended Mach 31, 2026”

Neonode Inc. reported three months ended March 31, 2026 results: revenue $0.6 million, net income $1.9 million, EPS $0.11 per share.

“Neonode Inc. (NASDAQ: NEON) (“Neonode” or the “Company”) today reported financial results for the three months ended March 31, 2026 . FINANCIAL SUMMARY FOR THE THREE MONTHS ENDED March 31, 2026 : ● Revenues from continuing operations of $0.6 million , an increase of 19.7% compared to the same period in the prior year. ● Operating expenses from continuing operations of $2.7 million , an increase of 8.6% compared to the same period in the prior year. ● Loss from continuing operations of $1.9 million , or $0.11 per share, compared to a loss of $1.8 million , or $0.11 per share, for the same period in the prior year.”

CIMG Inc. reported the quarterly period ended March 31, 2026 results: revenue $3.2 million.

“in the Asian market, and initially formed a synergistic development pattern between digital assets and new businesses. Total revenue for the quarter ended March 31, 2026 reached $3.2 million, representing substantial growth compared with the same period last year. Total revenue for the six months ended March 31, 2026 amounted to $18.9 million, surging 82,969% year”

BEASLEY BROADCAST GROUP INC reported Three Months Ended March 31, 2026 results: revenue $42.6 million, net income $3.2 million, EPS $1.77.

“Net revenue during the three months ended March 31, 2026 decreased 12.9% to $42.6 million, a decrease of 6.7% on a same-station basis. This performance reflects persistent weakness in the traditional agency advertising market that was partially offset by the continued expansion of our high-margin, owned-and-operated direct digital revenues. Beasley recorded operating income of $7.7 million in the first quarter of 2026, compared to an operating loss of $0.3 million in the prior year quarter. The increase in operating income was driven primarily by the completion of the company’s sale of all stations operated within Fort Myers, FL. Cash interest expense totaled $3.3 million, consistent with prior periods. Beasley reported net income of approximately $3.2 million, or $1.77 per diluted share, compared to a net loss of $2.7 million, or $1.50 per diluted share, in the prior year quarter.”

Lite Strategy, Inc. reported financial results for the fiscal 2026 third quarter ended March 31, 2026.

“On May 13, 2026, Lite Strategy, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended March 31, 2026.”

FATE THERAPEUTICS INC reported financial results for the first quarter ended March 31, 2026.

“On May 13, 2026, Fate Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.”

SS Innovations International, Inc. reported the three months ended March 31, 2026 results: revenue $11.1 million, EPS $(0.02) per diluted share.

“Report on Form 10-Q for the quarter ended March 31, 2026, with the Securities and Exchange Commission on May 13, 2026. First Quarter 2026 Overview ● Revenue increased 116.8% to $11.1 million from $5.1 million in the first quarter of 2025. ● Gross margin expanded to 48.0% from 21.2% in the first quarter of 2025. ● Gross profit rose 390.0% to $5.3 million from $1.1”

QT IMAGING HOLDINGS, INC. reported the three months ended March 31, 2026 results: revenue $6.5 million.

“QT Imaging Reports First Quarter 2026 Revenue of $6.5 Million”

ASTROTECH Corp reported financial results for third quarter of fiscal year 2026, which ended March 31, 2026.

“On May 13, 2026, Astrotech Corporation (the “Company”) issued a press release announcing its results of operations for its third quarter of fiscal year 2026, which ended March 31, 2026.”

Century Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net (loss) was $21.6 million for the quarter ended March 31, 2026, compared to net income of $76.6 million for the same.

“Century Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.”

BLOOMIA HOLDINGS, INC. reported the nine months ended March 31, 2026 results: revenue $26.3 million, net income $5.9 million, EPS $3.33 per diluted share.

“months ended March 31, 2025. ● EBITDA was $0.9 million compared to $2.6 million in the three months ended March 31, 2025. ​ Nine Months Ended March 31, 2026 ● Net revenue was $26.3 million compared to $25.3 million in the nine months ended March 31, 2025. ● Gross profit was $3.3 million, or 12.5% of sales, compared to $4.7 million, or 18.8% of sales, in the nine”

BLOOMIA HOLDINGS, INC. reported the third fiscal quarter ended March 31, 2026 results: revenue $14.4 million, net income $0.8 million, EPS $0.43 per diluted share.

“or the “Company”) today announced its financial results for the third fiscal quarter ended March 31, 2026. ​ Overview ​ Three Months Ended March 31, 2026 ● Net revenue was $14.4 million compared to $12.4 million in the three months ended March 31, 2025. ● Gross profit was $2.9 million, or 19.8% of sales, compared to $3.9 million, or 31.3% of sales, in the three”

SPRUCE BIOSCIENCES, INC. reported preliminary financial results for the first quarter ended March 31, 2026.

“On May 13, 2026, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026 and providing corporate updates.”

Xenetic Biosciences, Inc. reported the three months ended March 31, 2026 results: revenue approximately $0.8 million, net income approximately $0.5 million.

“Royalty revenue for the three months ended March 31, 2026 increased approximately 36% to approximately $0.8 million, compared to approximately $0.6 million for the comparable prior year period, primarily driven by increased royalty payments recognized under the Company’s sublicense agreement with Takeda Pharmaceuticals Co. Ltd.”

Protara Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $17.8 million, or $0.31 per share, EPS $0.31 per share.

“For the first quarter of 2026, Protara incurred a net loss of $17.8 million, or $0.31 per share, compared with a net loss of $11.9 million, or $0.29 per share, for the same period in 2025.”

Tyra Biosciences, Inc. reported financial results for first quarter ended March 31, 2026.

“On May 13, 2026, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.”

Local Bounti Corporation/DE reported the three months ended March 31, 2026 results: revenue $11.6 million, net income $37.7 million.

“great position to capture demand for efficient capacity as the industry continues its migration to CEA products.” First Quarter 2026 Financial Summary • Sales increased 15% to $13.3 million in the first quarter of 2026, as compared to $11.6 million in the prior year period. The increase was due to increased production and growth in sales from the facilities in”

Altimmune, Inc. reported the first quarter ended March 31, 2026 results: net income $22.6 million, or $0.18 net loss per share.

“Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its first quarter ended March 31, 2026.”

Arbutus Biopharma Corp reported quarter ended March 31, 2026 results: net income For the quarter ended March 31, 2026, the Company’s net income was $169.7 million, or income of $0.88 per basic and $0.8, EPS income of $0.88 per basic and $0.87 per diluted common share.

“Total revenue was $179.1 million for the quarter ended March 31, 2026, compared to $1.8 million for the same period in 2025.”

Arbutus Biopharma Corp reported first quarter ended March 31, 2026 results: revenue $179.1 million, net income $169.7 million, EPS income of $0.88 per basic and $0.87 per diluted common share.

“Revenue Total revenue was $179.1 million for the quarter ended March 31, 2026, compared to $1.8 million for the same period in 2025.”

VISHAY INTERTECHNOLOGY INC reported fiscal first quarter ended April 4, 2026 results: revenue $839.2 million, EPS $0.05. Guidance initiated.

“of discrete semiconductors and passive electronic components, today announced results for the fiscal first quarter ended April 4, 2026. Highlights • 1Q 2026 revenues of $839.2 million • Gross margin was 21.0% • 1Q 2026 GAAP EPS of $0.05 • 1Q 2026 book-to-bill of 1.34 with book-to-bill of 1.47 for semiconductors and 1.23 for passive components • Backlog at”

ABEONA THERAPEUTICS INC. reported first quarter ended March 31, 2026 results: revenue $8.7 million, net income $(17.1) million, EPS $(0.30) per basic and diluted common share.

“Abeona reported net product revenue of $8.7 million in the first quarter ending March 31, 2026.”

Milestone Pharmaceuticals Inc. reported the first quarter ended March 31, 2026 results: revenue $0.2 million.

“into the second half of 2027, including expenses expected in connection with the initiation of the Phase 3 trial in AFib-RVR, as described above. · Product revenues were $0.2 million during the three months ended March 31, 2026. There was no product revenue during the three months ended March 31, 2025. · Research and development expense for the first”

Charlotte's Web Holdings, Inc. reported financial results for the quarter ended March 31, 2026.

“On May 13, 2026, Charlotte’s Web Holdings, Inc. (the “Company”) issued an earnings release announcing its financial results for the three months ended March 31, 2026.”

Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2026 results: revenue $20.9 million, net income net loss was $3.1 million. Guidance raised.

“conditions, today reported financial and operating results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights ● Generated total revenue of $20.9 million for the first quarter of 2026, as compared to $32.9 million for the first quarter of 2025. The decline in revenue relates primarily to the sale of assets and businesses to”

PDS Biotechnology Corp reported the quarter ended March 31, 2026 results: net income net loss of approximately $7.3 million, EPS $0.13 per basic and diluted share.

“Reported net loss for the quarter ended March 31, 2026, was approximately $7.3 million, or $0.13 per basic and diluted share”

Upstream Bio, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $40.6 million for the quarter ended March 31, 2026.

“Net loss was $40.6 million for the quarter ended March 31, 2026, compared to a net loss of $27.3 million for the same period in 2025.”